Neil has over 30 years of drug development experience and currently serves on the boards of Instil Bio, Shattuck Laboratories and Adanate in addition to Causeway Therapeutics.

Dr. Gibson served as SVP of COI Pharmaceuticals an accelerator company focused on the creation and development of unique biotechnology companies from 2016-2021. This included serving as President and Chief Executive Officer of Adanate (2017-2021) and President and Chief Executive Officer of PDI Therapeutics (2017-2020).  Neil has also held various senior positions within the biotechnology and pharmaceutical industry at companies including BioAtla, Regulus Therapeutics, Pfizer Oncology, and OSI Pharmaceuticals. While at Pfizer, Neil was also a member of the Pfizer Oncology Business Unit Executive team.  Neil has been involved in the successful discovery, development, and commercialization of four approved oncology drugs, including temozolomide, sorafenib, erlotinib, and crizotinib. While at Regulus he was responsible for leading all research and development efforts resulting in three distinct oligonucleotides being advanced into clinical development and the establishment of human proof of concept with the lead molecule RG-101.

Neil has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, he has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Neil earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.